Cadrenal Therapeutics highlights new research on the economic and medical burden associated with oral anticoagulation for LVAD patients.

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients. ... Tecarfarin, with its novel metabolic pathway, ...

Many stroke risk factors are modifiable, but clinicians inconsistently apply guidelines and patients remain unaware of risks, ...

Non-valvular atrial fibrillation accounts for 13–26% of acute ischaemic strokes.1 Direct oral anticoagulants (DOACs) are highly effective in reducing the risk of ischaemic stroke with significantly ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Paul Daniels reviews the risk of hemorrhaging in patients receiving long-term anticoagulation therapy, and suggests management options that take into account the risk of venous thromboembolism.

The pathway to Hashem and the chain of transmission A talk with Rabbi David Samson about his new English series of commentaries on the meditative path of the Kabbalist Rabbi Avraham Abulafia.

Instead of approving Stealth BioTherapeutics' drug for Barth syndrome, the FDA withheld its endorsement, but decided it may be possible for Stealth to pursue accelerated approval.

A decade after San Diego Unified increased its graduation requirements, the district created an alternate graduation pathway that waters down those requirements. Some students now may not qualify for ...